Read Original Release

Announcement on fortified food for acute malnutrition neglects to mention patents held by study authors

Rating

2 Star

New research to treat acute malnutrition

Our Review Summary

This news release describes a study published in PLOS Medicine, showing that among moderate acute malnourished infants lipid-based nutrient supplement (LNS)–a kind of fortified peanut butter–produced more gain in muscle and organ weight over 12 weeks than a corn-soy blend (CSB) porridge. Acute malnutrition affects over 50 million children across the world. It is characterized by bodily wasting following experience of a recent period of starvation.

According to the researchers, until now there has been concern that because LNS has a very high fat content any weight gain it produced would be composed primarily of fat. The distinction of this study is its demonstration that LNS not only resulted in more weight gain, but that weight gain was in muscles and organs (lean mass) rather than fat.

 

Why This Matters

Children with the most severe level of acute malnutrition are at risk of death. Increasing the effectiveness of interventions with children before their malnutrition becomes severe could save millions of lives. However, readers would take away a better understanding of this critical issue if more space in this news release had been devoted to explaining the study itself, and less to citing various researchers and partners about how important the project was.

Criteria

Does the news release adequately discuss the costs of the intervention?

Not Satisfactory

No comparison is made in the news release between the cost of the current corn-soy blend (CSB) nutrient supplement and the alternative lipid-based supplement. This is strange considering that the original study devotes some space to addressing the issue of cost-effectiveness. The researchers conclude that although LNS is about twice as expensive as CSB, the possibility that it could require a shorter treatment regimen, is easier to prepare, and has a longer shelf life could make it more cost-effective in the long run. They call for detailed cost-effectiveness studies to inform policy decisions, a point that goes unmentioned in the release.

Does the news release adequately quantify the benefits of the treatment/test/product/procedure?

Not Satisfactory

The primary outcome in this study was weight gain that was not primarily fat; it is important to note that this study did not address survival or neurodevelopment, which are the presumed benefits of greater fat-free weight gain. The news release tells us that children who received LNS gained more weight than children on the corn-soy porridge, and that weight was primarily lean mass. It doesn’t tell us how much more weight they gained, nor does it describe the difference in progression to severe acute malnutrition. Studies with large samples like this one can give results that are statistically significant even when differences are small. Specific information about the size and clinical importance of the difference should have been included.

Does the news release adequately explain/quantify the harms of the intervention?

Not Satisfactory

Many people’s first question upon reading about a peanut buttery kind of nutrient supplement might be whether it produced any allergic reaction or other side effects in infants. In fact, it didn’t, but the news release doesn’t tell us that.

Does the news release seem to grasp the quality of the evidence?

Satisfactory

Readers are told there were two arms of the study, the treatment lasted for 12 weeks, and children’s lean mass was assessed afterward. It would have been better if the news release mentioned that children were randomly assigned to treatment. Nevertheless, the basics for understanding how the study was conducted are provided.

Does the news release commit disease-mongering?

Satisfactory

No mongering here. It would be pretty much impossible to engage in disease mongering about acute malnutrition.

Does the news release identify funding sources & disclose conflicts of interest?

Not Satisfactory

The major funding sources for the study are listed, but financial relationships between two of the authors and Nutriset, a producer of LNS products, were not included in the release. According to the published study they are Nutriset patent holders.

Does the news release compare the new approach with existing alternatives?

Satisfactory

The study is all about comparing widely used alternatives about which there have been long standing questions of relative benefit.

Does the news release establish the availability of the treatment/test/product/procedure?

Satisfactory

The news release assumes availability of both types of supplements, though no specific information is provided about how much each is currently used for treatment of moderate acute malnutrition in infants.

Does the news release establish the true novelty of the approach?

Not Satisfactory

This piece gives the impression that across the globe most current interventions for infants with moderate acute malnutrition use CSB as a nutritional supplement. The original study itself presents a somewhat different picture, noting that there is currently no consensus on which of the two food supplements is better, and citing a World Health Organization recommendation that more research needs to be done.

Does the news release include unjustifiable, sensational language, including in the quotes of researchers?

Not Satisfactory

The news release claims in the first paragraph that “corn-soy porridge should be replaced with  a lipid-based nutrient supplement (LNS)” [emphasis ours]. The researchers in the original study are careful to qualify their recommendation with the need for a cost-effectiveness analysis as well as more study about the role of soy and milk in food supplements. We’d like to have seen correspondingly moderate claims in the news release.

Total Score: 4 of 10 Satisfactory

Comments

We Welcome Comments. But please note: We will delete comments left by anyone who doesn’t leave an actual first and last name and an actual email address.

We will delete comments that include personal attacks, unfounded allegations, unverified facts, product pitches, or profanity. We will also end any thread of repetitive comments. Comments should primarily discuss the quality (or lack thereof) in journalism or other media messages about health and medicine. This is not intended to be a forum for definitive discussions about medicine or science. Nor is it a forum to share your personal story about a disease or treatment -- your comment must relate to media messages about health care. If your comment doesn't adhere to these policies, we won't post it. Questions? Please see more on our comments policy.